Pacira Pharmaceuticals (PCRX) in Focus: Stock Jumps 5.3% - Tale of the Tape
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise over 5% on the day. Shares rose on the announcement of the company’s second-quarter 2015 results wherein earnings of 20 cents per share were in line with estimates. The news led to far more shares changing hands than in a normal session resulting in solid volume. This reverses the recent trend for the company as the stock is now down 11.7% in the past one-month time frame.
None of the estimates for this medical drugs stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Pacira Pharmaceuticals currently carries a Zacks Rank #4 (Sell).
A better-ranked stock in the same industry is Cardiome Pharma Corp. (CRME), sporting a Zacks Rank #1 (Strong Buy).
Is PCRX going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PACIRA PHARMACT (PCRX): Free Stock Analysis Report
CARDIOME PHARMA (CRME): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
